SFV Healthcare

Earnings: Apollo Medical Holdings, ImmunoCellular Therapeutics

Apollo Medical revenue grows 236 percent, ImmunoCellular trims losses.

MannKind Moving to Westlake Village

Valencia biopharmaceutical company MannKind Corp. is relocating its corporate headquarters to Westlake Village, the company confirmed Thursday.

SetPoint Medical Hires Clinical Exec

SetPoint Medical on Monday announced that it has appointed Terry Bevirt as vice president of clinical affairs.

Sienna Shares Rise on IPO Day

Sienna Biopharmaceuticals Inc. debuted on the Nasdaq Thursday with its shares gaining nearly 30 percent on its first day of trading.

Amgen Tops Wall St. Expectations

Amgen Inc. beat Wall Street’s expectations on Tuesday with its second-quarter financial results.

Simi Medical Building Sold

Rand Medical Building in Simi Valley has sold for $2.9 million, according to commercial brokerage Marcus & Millichap in Calabasas.

FDA Accepts Amgen's Aimovig Application

Amgen Inc. on Thursday announced that the U.S. Food and Drug Administration has accepted the biologics license application for Aimovig, a drug for prevention of migraine.

Amgen Collaboration on Cancer Drugs

Amgen Inc. on Tuesday announced a collaboration agreement with Array BioPharma for development of drugs for autoimmune disorders.

MannKind Names CFO

MannKind Corp. on Monday announced that Steven Binder has joined the company as chief financial officer.

FDA Approves Amgen Leukemia Drug

Amgen Inc.’s leukemia drug Blincyto has received full approval from the U.S. Food and Drug Administration, the company has announced.

MannKind Selects Chief Commercial Officer

MannKind Corp. on Wednesday announced that Patrick McCauley will join the company as chief commercial officer.

Cure, Israelis Partner on Pot Research

Cure Pharmaceuticals on Tuesday announced that it has signed a memorandum to enter into a research collaboration with two Israeli companies.

Revenue, Income Rise at Simulations Plus

Simulation Plus Inc. on Monday reported fiscal third-quarter earnings that showed rising revenue and net income.

Sienna Biopharmaceuticals Files for IPO

Sienna Biopharmaceuticals Inc. on Monday filed paperwork with the Securities and Exchange Commission for an initial public offering to raise up to $74.8 million.

Monster Digital Signs Reverse Merger Deal

Monster Digital Inc. has signed a definitive merger agreement with privately held Innovate Biopharmaceuticals Inc., prompting 160 percent gain in its stock price Monday.

Sections

More LA Business Journal